Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.

Journal article

As a target for gene therapy, Duchenne muscular dystrophy (DMD) presents many obstacles but also an unparalleled prospect for correction by alternative splicing. The majority of mutations in the dystrophin gene occur in the region encoding the spectrin-like central rod domain, which is largely dispensable. Thus, splicing around mutations can generate a shortened but in-frame transcript, permitting translation of a partially functional dystrophin protein. We have tested this idea in vivo in the mdx dystrophic mouse (carrying a mutation in exon 23 of the dystrophin gene) by combining a potent transfection protocol with a 2-O-methylated phosphorothioated antisense oligoribonucleotide (2OMeAO) designed to promote skipping of the mutated exon*. The treated mice show persistent production of dystrophin at normal levels in large numbers of muscle fibers and show functional improvement of the treated muscle. Repeated administration enhances dystrophin expression without eliciting immune responses. Our data establishes the realistic practicality of an approach that is applicable, in principle, to a majority of cases of severe dystrophinopathy.

Authors: Lu, Q; Mann, C; Lou, F; Bou-Gharios, G; Morris, G

• Publication status: Published
• Journal: Nature medicine
• Volume: 9
• Issue: 8
• Pages: 1009-1014
• Publication date: 2003-08-01
• DOI: 10.1038/nm897
• EISSN: 1546-170X
• ISSN: 1078-8956
• Language: English
• Keywords: RNA Splicing; Mutation; Gene Expression Regulation; Muscular Dystrophy, Animal; Oligonucleotides, Antisense; Muscle, Skeletal; Humans; Genetic Therapy; Mice; Muscular Dystrophy, Duchenne; Exons; Dystrophin; Animals; Mice, Inbred mdx